Sanjivani Paranteral Ltd

Sanjivani Paranteral Limited has a liquidity ratio of 1.08, indicating a moderate ability to meet short-term obligations, and a debt-to-equity ratio of 0.21, suggesting a relatively low level of financial leverage. The company's return on equity is 21.3%, and return on assets is 10.35%, which are metrics that reflect the company's profitability and efficiency in using its assets. The company's profitability, as measured by return on equity and return on assets, is in line with the industry's preferred metrics, indicating that Sanjivani Paranteral Limited is performing at a level comparable to its peers in the Pharmaceuticals industry. The company's gross profit margin is 42.26%, and its operating margin is 13.89%, which are key indicators of the company's operational efficiency and pricing power. Sanjivani Paranteral Limited's revenue is derived from a diverse range of pharmaceutical products, including antibiotics, anti-emetics, and NSAIDs, with no specific segment or geographic region dominating the revenue stream. The company's product portfolio is broad, covering various therapeutic areas, which may help in mitigating the risk associated with any single product or market. The company's growth trajectory is not explicitly detailed in the provided data, but the financial snapshot indicates a net income of 80,943,430 INR, suggesting a profitable operation. The company's free cash flow is negative at -216,332,510 INR, which may indicate that the company is investing heavily in its operations or facing high capital expenditures. The risk assessment for Sanjivani Paranteral Limited indicates a medium level of liquidity risk and a low level of dilution risk. The company's key flags include a negative net cash position after subtracting total debt, which may affect its ability to fund operations without external financing. The company's capital structure, with a long-term debt of 81,418,230 INR and total equity of 379,960,290 INR, suggests a conservative approach to financing. Recent events for Sanjivani Paranteral Limited are not detailed in the provided data, but the company's financial performance and risk profile suggest that it is a stable and profitable entity in the Pharmaceuticals industry. The company's financial health is supported by its operating cash flow of 124,022,700 INR, which is a positive indicator of its ability to generate cash from its core operations.